NCT00446797 - Open Label Comparative Study On Celecoxib Efficacy And Safety Vs Non-Selective NSAID In Acute Pain Due To Ankle Sprain | Biotech Hunter

Enrollment

278

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

April 30, 2008

Study Completion Date

April 30, 2008

Conditions

Ankle Sprain

Interventions

DRUG

Non-selective NSAIDS

Non-selective NSAIDs administered at usual (standard) doses.

DRUG

Celecoxib

celecoxib with an initial loading dose of 400 mg followed by 200 mg twice daily (BID) for up to 7 days.

Trial Locations (16)

10700

Pfizer Investigational Site, Mexico City

50180

Pfizer Investigational Site, Toluca

66451

Pfizer Investigational Site, San Nicolás de los Garza

74075-020

Pfizer Investigational Site, Goiânia

20221-161

Pfizer Investigational Site, Rio de Janeiro

01221-900

Pfizer Investigational Site, São Paulo

02720-000

Pfizer Investigational Site, São Paulo

Unknown

Pfizer Investigational Site, San Antonio Guadalupe

Pfizer Investigational Site, Quito

Pfizer Investigational Site, Cairo

Pfizer Investigational Site, Panama City

11181 Jordan

Pfizer Investigational Site, Amman

11193 Jordan

Pfizer Investigational Site, Amman

22110 Jordan

Pfizer Investigational Site, Amman

03020

Pfizer Investigational Site, México DF

L27

Pfizer Investigational Site, Lima

All Listed Sponsors

lead

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

INDUSTRY